20(S)-protopanaxatriol, one of ginsenoside metabolites, inhibits inducible nitric oxide synthase and cyclooxygenase-2 expressions through inactivation of nuclear factor-κB in RAW 264.7 macrophages stimulated with lipopolysaccharide

被引:71
作者
Oh, GS
Pae, HO
Choi, BM
Seo, EA
Kim, DH
Shin, MK
Kim, JD
Kim, JB
Chung, HT [1 ]
机构
[1] Wonkwang Univ, Sch Med, Dept Microbiol & Immunol, Iksan 570749, Chonbuk, South Korea
[2] Wonkwang Univ, Med Resources Res Ctr, Iksan 570749, Chonbuk, South Korea
[3] Wonkwang Univ, Sch Med, Dept Ophthalmol, Iksan 570749, Chonbuk, South Korea
[4] Wonkwang Pharmaceut Co Ltd, Iksan, Chonbuk, South Korea
关键词
Panax ginseng; ginsenoside; 20(S)-protopanaxatriol; inducible nitric oxide synthase; cyclooxygenase-2; nuclear factor-kappa B; inflammation; chemoprevention;
D O I
10.1016/j.canlet.2003.09.037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ginsenosides from Panax ginseng are metabolized by human intestinal bacteria after oral administration of ginseng extract. 20(S)-Protopanaxatriol (PPT) is one of the major metabolites of ginsenosides. Inducible nitric oxide synthase (NOS) and cyclooxygenase-2 (COX-2) are important enzymes that mediate inflammatory processes. Improper up-regulation of iNOS and/or COX-2 has been associated with the pathogenesis of inflammatory diseases and certain types of human cancers. Here, we investigated whether PPT could modulate NOS and COX-2 expressions in RAW 264.7 macrophages stimulated with the endotoxin lipopolysaccharide (LPS). We found that PPT blocked the increase in LPS-induced iNOS and COX-2 expressions through inactivation of nuclear factor-kappaB by preventing I-kappaBalpha phosphorylation and degradation. Thus, it may be possible to develop PPT as a useful agent for chemoprevention of cancer or inflammatory diseases. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:23 / 29
页数:7
相关论文
共 31 条
  • [1] Ginseng pharmacology - Multiple constituents and multiple actions
    Attele, AS
    Wu, JA
    Yuan, CS
    [J]. BIOCHEMICAL PHARMACOLOGY, 1999, 58 (11) : 1685 - 1693
  • [2] Nuclear factor-kappa B and cancer: its role in prevention and therapy
    Bharti, AC
    Aggarwal, BB
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) : 883 - 888
  • [3] Bing RJ, 2001, CLIN CANCER RES, V7, P3385
  • [4] Transcription factors as targets for cancer therapy
    Darnell, JE
    [J]. NATURE REVIEWS CANCER, 2002, 2 (10) : 740 - 749
  • [5] The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line
    Fantappiè, O
    Masini, E
    Sardi, I
    Raimondi, L
    Bani, D
    Solazzo, M
    Vannacci, A
    Mazzanti, R
    [J]. HEPATOLOGY, 2002, 35 (04) : 843 - 852
  • [6] Inflammation and the development of pancreatic cancer
    Farrow, B
    Evers, BM
    [J]. SURGICAL ONCOLOGY-OXFORD, 2002, 10 (04): : 153 - 169
  • [7] Correlation between nitric oxide and cyclooxygenase-2 pathways in head and neck squamous cell carcinomas
    Gallo, O
    Fabbroni, V
    Sardi, I
    Magnelli, L
    Boddi, V
    Franchi, A
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 299 (04) : 517 - 524
  • [8] Rel/NF-κB/IκB signal transduction in the generation and treatment of human cancer
    Gilmore, T
    Gapuzan, ME
    Kalaitzidis, D
    Starczynowski, D
    [J]. CANCER LETTERS, 2002, 181 (01) : 1 - 9
  • [9] Main Ginseng saponin metabolites formed by intestinal bacteria
    Hasegawa, H
    Sung, JH
    Matsumiya, S
    Uchiyama, M
    [J]. PLANTA MEDICA, 1996, 62 (05) : 453 - 457
  • [10] Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol
    Hasegawa, H
    Suzuki, R
    Nagaoka, T
    Tezuka, Y
    Kadota, S
    Saiki, I
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2002, 25 (07) : 861 - 866